7 citations
,
January 2021 in “Dermatology and therapy” This study confirmed that the Alopecia Areata-Investigator Global Assessment and other clinical outcome assessments are valid and relevant measures of treatment success for alopecia areata patients in Japan, aligning with previous North American findings.
3 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” This study found that scalp hair loss is the most bothersome symptom of alopecia areata for both adults and adolescents, highlighting the need for treatments focused on improving scalp hair growth.
30 citations
,
September 2020 in “Journal of Patient-Reported Outcomes” This study found that alopecia areata significantly impacts emotional and psychological well-being, relationships, and lifestyles, highlighting the need for increased awareness and effective treatments.
56 citations
,
August 2020 in “American Journal of Clinical Dermatology” This study concluded that the ClinRO and PRO measures, along with their photoguides, offer clear and meaningful assessments for patients with alopecia areata concerning eyebrow, eyelash, and nail appearance, as well as eye irritation.
86 citations
,
January 2020 in “British Journal of Dermatology” This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.
58 citations
,
January 2018 in “International Journal of Women's Dermatology” This review discusses the psychological impact of alopecia on women and reports no new clinical findings, highlighting the effect on self-esteem and quality of life.
222 citations
,
September 2016 in “JCI insight” This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.
196 citations
,
September 2016 in “JCI insight” This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.
95 citations
,
July 2016 in “Journal of The American Academy of Dermatology” This review concluded that patients with alopecia areata consistently show poor health-related quality of life scores, similar to those in other chronic skin diseases like atopic dermatitis and psoriasis.
128 citations
,
February 2016 in “British Journal of Dermatology” This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.
66 citations
,
May 2011 in “Dermatologic therapy” This report discusses guidelines for designing alopecia clinical trials that account for variables affecting results, but it presents no new efficacy findings.